This content is from: Corporate

US banks should change their CFD terms

Derivative poison pills may face questions of validity in court, but US banks should change the terms of their CFDs anyway

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.

REQUEST ACCESS

Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial